依达拉奉联合神经节苷脂治疗急性脑梗死的疗效观察

The efficacy of edaravonc combined with gangliosidc for acute cerebral infarction

目的探讨依达拉奉联合神经节苷脂治疗急性脑梗死的临床疗效。方法选取2007年6月至2010年6月急性脑梗死患者138例，并随机分为观察组69例与对照组69例，对照组给予常规治疗并给予阿司匹林抗血小板，聚集、控制血压、血糖及脱水降颅压及保护脑细胞、改善循环、使用甘露醇、丹参、胞二磷胆碱等治疗；观察组在常规治疗的基础上加用依达拉奉联合神经节苷脂。所有病例于治疗前后用美国国立卫生院卒中患者神经机能缺损评分量表（National Institutes of Health Stroke，NIHSS）评分。结果治疗21d后，观察组总显效率为82．61％，总有效率为94．41％；对照组总显效率为31．88％，总有效率为39．13％，两组比较差异有统计学意义（P〈0．05），观察组NIHSS评分与对照组比较差异有统计学意义（P〈0．05）.结论依达拉奉联合神经节苷脂治疗急性脑梗死不但安全有效，而且能更好地提高神经功能恢复，对脑组织有显著保护作用，并降低致残率，提高患者生活质量。

Objective To explore the efficacy of edaravone combined with ganglioside for acute cerebral infarction. Methods 138 patients with acute cerebral infarction from June 2007 to June 2010 were randomly divided into study group and control group, 69 patients for each group. The control group received conventional therapy, aspirin for controlling blood platelets, control of blood pressure and sugar and water to intracranial hypotension, protection of cerebral cells, and improvement of circulation, mannitol, salvia mihiorrhiza, and citicoline, The study group on the edaravone plus ganglioside besides conventional therapy. All the patients were assessed using National Institutes of Health Stroke before and after treatment, Results 21 days after therapy, the overall response rate was 82.61% in the study group and 31.88% in the control group, and the total effective rate was 94.41% and 39.13%, respectvels there was a statistical difference between the two groups （P〈0.05）. Scores for NIHSS differed significantly between the two groups （P〈0.05）. Conclusions Edaravone combined with ganglioside for acute cerebral infarction is safe and effective and can increase the recovery of nerve function, protect the cerebral tissue, reduce disability rate, and improve the quality of life.